Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals (SUPN) is a leading biopharmaceutical innovator focused on developing advanced treatments for central nervous system disorders. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives in neurology and psychiatry.
Access comprehensive coverage of SUPN's progress in treating epilepsy, ADHD, and movement disorders through reformulated therapeutics. Our curated news feed includes updates on FDA submissions, partnership announcements, clinical trial results, and market expansion efforts – all essential for understanding the company's position in CNS therapeutics.
Key areas of focus include non-stimulant ADHD treatments, extended-release neurology medications, and novel approaches to Parkinson's-related conditions. Stay informed about SUPN's pipeline advancements and commercial strategies through verified press releases and objective analysis.
Bookmark this page for direct access to Supernus Pharmaceuticals' latest developments in neuroscience innovation. Check regularly for updates on product approvals, research collaborations, and financial performance indicators relevant to CNS treatment advancements.
Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its upcoming third quarter 2022 financial results, set to be reported after market close on November 8, 2022. CEO Jack Khattar and CFO Tim Dec will host a conference call to discuss the results at 4:30 p.m. ET on the same day.
The call will be available via live webcast on the company's Investor Relations website, where a replay will also be accessible for 60 days following the event.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA issued a Complete Response Letter (CRL) for its SPN-830 New Drug Application (NDA). This investigational apomorphine infusion device targets motor fluctuations in Parkinson's disease. The CRL requests further information about labeling, product quality, and device performance. Notably, the FDA's initial findings do not ask for additional efficacy and safety studies. Supernus aims to address the FDA's concerns and expedite the NDA resubmission, which will undergo a six-month review timeline.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET. The conference runs from September 7-9, 2022, at Encore Boston Harbor, Massachusetts. Investors can access a live audio webcast of the presentation via the Company’s website, with an archived replay available for 60 days. Supernus focuses on developing treatments for central nervous system diseases.
Supernus Pharmaceuticals reported Q2 2022 revenues of $170.1 million, reflecting a 20% increase year-over-year. The company's GAAP operating earnings stood at $11.3 million, down from $34.1 million in Q2 2021. Notably, Qelbree prescriptions surged to 62,938, marking a 33% increase from Q1 2022. Net product sales for Qelbree grew by 34% quarter-over-quarter, reaching $11.1 million. The company maintains a robust cash position of $508.2 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced the upcoming release of its financial and business results for Q2 2022 on August 4, 2022, after market close. The conference call, hosted by President and CEO Jack Khattar and CFO Tim Dec, will begin at 4:30 p.m. ET. Investors can pre-register for the call and access a live webcast through the company's Investor Relations website. Supernus is focused on CNS disease treatments and is advancing a range of product candidates for various neurological disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO Jack Khattar will lead the presentation, highlighting the company’s focus on CNS diseases.
Investors can arrange meetings through the conference coordinator. The event occurs from June 8-10, 2022, at the New York Marriott Marquis. A live audio webcast will be available on the company's website, with a replay for 60 days post-conference. Supernus is known for its CNS product portfolio, including treatments for epilepsy, migraines, and Parkinson’s disease.
Supernus Pharmaceuticals reported first quarter 2022 revenues of $152.5 million, a 16% increase year-over-year. Net earnings rose to $25.6 million or $0.43 per diluted share. GAAP operating income stood at $2.0 million, while non-GAAP operating income was $28.0 million, reflecting an 11% increase from 2021. The FDA approved Qelbree® for adult ADHD treatment, contributing to 47,324 prescriptions in Q1, a 38% increase from Q4 2021. Financial guidance for 2022 remains $640 - $680 million in total revenues.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report Q1 2022 financial results after the market closes on May 9, 2022. President and CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results, with a Q&A session following. A live webcast will be available on the Supernus website. The company specializes in developing CNS disease treatments, including products for epilepsy, migraine, and Parkinson’s disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced FDA approval for Qelbree (viloxazine) to treat ADHD in adults, marking the first new nonstimulant treatment in 20 years. ADHD impacts 10 million adults in the U.S., with up to 90% of diagnosed children continuing into adulthood. The approval follows positive Phase III trial results, demonstrating significant symptom reduction compared to placebo (p=0.0040). Qelbree, a once-daily capsule, has shown a favorable safety profile, but may increase suicidal thoughts in some patients.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
